A growing portfolio to increase patient access to high quality treatments
We are specialists in biologics: we have developed and commercialized two biosimilar medicines for oncology, available to thousands of patients across the globe via our B2B partnerships in worldwide markets: MB01 rituximab biosimilar and MB02 bevacizumab biosimilar, since 2014 and 2016 respectively. Now we have a highly attractive pipeline of biosimilar and innovative biopharmaceuticals targeting areas of oncology, hematology, osteoporosis and pediatrics.
Our development of biopharmaceuticals adheres to a strict “quality by design” standard using the latest innovations in upstream, downstream and cutting edge-analytics. We guarantee all biosimilars are equivalent in terms of quality, safety and efficacy to the reference products, by subjecting the drugs to exhaustive comparability testing and clinical trials, regulated by the competent authorities.